Hypertrophic Pachymeningitis Associated with Myeloperoxidase-anti-neutrophil Cytoplasmic Antibodies Induced by Propylthiouracil

A 71-year-old man with hyperthyroidism complained of headache lasting two months. He had been using propylthiouracil (PTU) for 14 years. Treatment intensification did not improve the symptoms. Blood tests detected a positive myeloperoxidase-anti-neutrophil cytoplasmic antibody (MPO-ANCA). Diffuse dural thickening was identified by magnetic resonance imaging. The patient was diagnosed with hypertrophic pachymeningitis (HP) due to ANCA-associated vasculitis (AAV). He received methylprednisolone pulse therapy followed by prednisolone and methotrexate, which improved his headache. PTU-induced AAV-related HP is a rare and indiscernible disease. Therefore, the possibility of the disease should be proactively considered when a PTU user experiences refractory headaches.

[1]  A. Aouba,et al.  A Worldwide Pharmacoepidemiologic Update on Drug‐Induced Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in the Era of Targeted Therapies , 2021, Arthritis & rheumatology.

[2]  K. Sugino,et al.  Propylthiouracil-induced otitis media with anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report and review of the literature. , 2020, Endocrine journal.

[3]  T. Matsunobu,et al.  Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) proposed by Japan otological society. , 2020, Auris, nasus, larynx.

[4]  N. Vila-Chã,et al.  Clinical features of hypertrophic pachymeningitis in a center survey , 2019, Neurological Sciences.

[5]  M. Bando,et al.  2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis , 2018, Modern rheumatology.

[6]  D. Glinoer,et al.  Antineutrophil Cytoplasmic Antibody-Positive Small-Vessel Vasculitis Associated with Antithyroid Drug Therapy: How Significant Is the Clinical Problem? , 2015, Thyroid : official journal of the American Thyroid Association.

[7]  K. Fujii,et al.  A nationwide survey of hypertrophic pachymeningitis in Japan , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[8]  M. Kasahara,et al.  Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. , 2012, Arthritis and rheumatism.

[9]  Kunihiko Ito,et al.  Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. , 2009, The Journal of clinical endocrinology and metabolism.

[10]  N. Kamel,et al.  Prevalence and clinical significance of antineutrophil cytoplasmic antibody in Graves’ patients treated with propylthiouracil , 2009, International journal of clinical practice.

[11]  S. Nogawa,et al.  Cerebral pachyleptomeningitis associated with MPO-ANCA induced by PTU therapy. , 2007, Internal medicine.

[12]  N. Yoshioka,et al.  Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole. , 2002, Endocrine journal.

[13]  A. McElduff,et al.  Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. , 2000, European journal of endocrinology.

[14]  S. Kobayashi,et al.  Pachymeningitis with a perinuclear antineutrophil cytoplasmic antibody: Response to pulse steroid , 1998, Neurology.

[15]  C. Kallenberg,et al.  Anca associated vasculitis: occurrence, prediction, prevention, and outcome of relapses , 2001 .